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The neglected tropical diseases (NTDs) thrive mainly among the poorest populations of the
world. The World Health Organization (WHO) has set ambitious targets for eliminating
much of the burden (and the transmission when possible) of these diseases by 2020 [1], with
new targets for 2030 being currently set [2]. Substantial international investment has been
made with the London Declaration (2012) on NTDs to prevent the morbidity and premature
mortality associated with these diseases through global programmes for their control and
elimination.
The NTD Modelling Consortium [3] is an international effort to improve the health of the
poorest populations in the world through the development and application of mathematical
(including statistical and geographical) models for NTD transmission and control.
Although policy and intervention planning for disease control efforts have been supported
by mathematical models [4–6], our general experience is that modelling-based evidence still
remains less readily accepted by decision-making bodies than expert opinion or evidence from
empirical research studies. Toward increasing modelling impact, we (1) conducted a review of
the literature on (health-related) modelling principles and standards, (2) developed recom-
mendations for areas of communication in policy-driven modelling to guide NTD pro-
grammes, and (3) presented this to the wider NTD Modelling Consortium.
Principles were formed as a guide for areas to communicate the quality and relevance of
modelling to stakeholders. It is not guidance for communicating models to other modellers or
how to conduct modelling. In adhering to a practise of these principles, our hope is that
modelling will be of greater use to policy and decision makers in the field of NTD control, and
possibly beyond that.
PLOS NEGLECTED TROPICAL DISEASES







Citation: Behrend MR, Basa´ñez M-G, Hamley JID,
Porco TC, Stolk WA, Walker M, et al. (2020)
Modelling for policy: The five principles of the
Neglected Tropical Diseases Modelling
Consortium. PLoS Negl Trop Dis 14(4): e0008033.
https://doi.org/10.1371/journal.pntd.0008033
Editor: Jesse Blanton, Centers for Disease Control
and Prevention, UNITED STATES
Published: April 9, 2020
Copyright: © 2020 Behrend et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Funding: M-GB, JIDH, TCP, WAS, MW, and SJV
gratefully acknowledge funding of the NTD
Modelling Consortium by the Bill and Melinda
Gates Foundation (OPP1184344). M-GB and JIDH
gratefully acknowledge joint Centre funding from
the UK Medical Research Council and the
Department for International Development (grant
no. MR/R015600/1). MRB gratefully acknowledges
the support of a Bill and Melinda Gates Foundation
consultancy (#52577). The funders had no role in
study design, data extraction and analysis, decision
to publish, or preparation of the manuscript.
Competing interests: I have read the journal’s
policy and the authors of this manuscript have the
Examples of successes in modelling for policy in the field of NTDs
We first wish to recognise some of the successful examples of NTD programme relationships
with modellers. The motivation for employing principled communication, as we propose, is to
deliver a similarly positive impact consistently over time and for different NTDs. Onchocercia-
sis (a filarial disease caused by infection with Onchocerca volvulus and transmitted by blackfly,
Simulium, vectors) probably provides the best example of impactful modelling, with its long
history of using evidence—mostly from the ONCHOSIM and EPIONCHO transmission mod-
els [7]—to support decision-making within ongoing multicountry control initiatives (Table 1).
From the start of the NTD Modelling Consortium in 2015, there have been several other
examples of impactful modelling, which could be divided over three major scales of operations:
(1) developing WHO guidelines (e.g., for triple-drug therapy, with ivermectin, diethylcarbam-
azine, and albendazole, against lymphatic filariasis [16, 17]); (2) informing funding decisions
for new intervention tools (e.g., the development of a schistosomiasis vaccine [18]); and (3)
guiding within-country targeting of control (e.g., local vector control for human African try-
panosomiasis in the Democratic Republic of the Congo [19, 20] and Chad [21]).
Methods
Literature review
Our review aimed to inform the present synthesis of principles for the consortium. We evalu-
ated published guidelines for good modelling practises in health-related modelling through a
review and qualitative synthesis, following a systematised approach. We searched Equator Net-
work Library for Health Research Reporting and PubMed with terms targeting guidance and
good practises for mathematical modelling in the area of human health. The PubMed search
applied the systematic[sb] filter with title-and-abstract terms (guideline� OR guidance OR
reporting OR checklist OR ((best OR good) AND practice�))) AND model� NOT animal, plus
any one of a combination of common modelling terms occurring in the full text. The full
search strategy is described in S1 Appendix (Literature review search strategy and Search strat-
egy and selection criteria). Studies in the form of reviews and guidelines were eligible for con-
sideration, and those discussing modelling in the abstract or title were included. Results were
then expanded by including references included in recent systematic and rapid reviews [22,
23]. Succinct statements were extracted for analysis, excluding elaborative text. Text was cop-
ied and pasted from PDF files to standardised study extraction spreadsheets.
We identified 288 studies relevant to modelling practises, of which 57 were included [24–
80] (Fig 1). See S1 Appendix (Table 1) for characteristics of included studies. Studies in the
form of reviews and guidelines were eligible for consideration, and those discussing modelling
conduct or reporting in the abstract or title were included. Studies were excluded if guidance
to modellers was not presented in a list or table to facilitate inspection. However, exclusions
were most frequently due to absence of guidance to modellers rather than because guidance
was not provided in a structured format. Altogether, included studies contained 1,054 succinct
statements of modelling guidance that were included in the qualitative synthesis. A summary
of the data set contents is given visually (Fig 2) and as a table of word occurrence counts in S1
Appendix (Table 2).
Scoring the guidance statements
Authors coded the data set individually (MRB, TCP, WAS, SJdV) and jointly (M-GB, JIDH,
MW), producing five independently coded sets of data (S1 Table). Modelling guideline state-
ments were coded with the following ordinal scale of importance scores: 1, not applicable; 2,
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not necessary; 3, important; 4, extremely important; and 5, obvious (i.e., merely restates princi-
ples regarded as universally agreed upon; see S1 Table).
In coding the data set, we saw that many of the 1,054 statements rephrased the same con-
cepts (e.g., ‘do an uncertainty analysis’). Statements similar in meaning could be given differ-
ent scores simply because they were phrased differently (S1 Appendix, Interrater reliability).
We rank-sorted statements by score to select the top few statements we collectively consid-
ered extremely important. A group of 46 statements consistently received a score of 4
(extremely important) from at least four of the authors. The most important 46 ranked state-
ments were selected, evaluated for content, and gradually categorised into five major themes
(S2 Table) through discussion. In each theme, we formulated a single principle that distilled
the statements grouped under that theme. Original text for each statement was preserved up to
this final stage of our synthesis. Preliminary formulations of the principles were discussed with
a subset of the larger NTD Modelling Consortium group at a meeting in New Orleans (28
October 2018) and further refined for presentation at the consortium Technical Meeting in
Oxford (20 March 2019).
Five of the 46 guidance statements at the top of our ranked list did not fit well into the cate-
gories we settled upon for principles. From those that did not become part of a principle, we
formed two philosophies that reflect some of our ideals. These will be presented in the
Discussion.
Table 1. Onchocerciasis modelling and policy impact.
Specific public health challenge How modelling addressed the challenge
What is the minimal duration of the OCP necessary to
mitigate the risk of recrudescence after cessation of
interventions?
ONCHOSIM guided duration of vector control
operations in the OCP and investigated the combined
impact of vector and ivermectin treatment to reduce
programme duration (1997) [5].
What is the feasibility of reaching elimination of
onchocerciasis transmission based on ivermectin
distribution as the sole intervention (i.e., in the absence
of vector control)?
ONCHOSIM informed the Conceptual and Operational
Framework of Onchocerciasis Elimination with
Ivermectin Treatment launched by the APOC (2010)
[8], and EPIONCHO and ONCHOSIM were fitted to
data from proof-of-principle elimination studies in foci
of Mali and Senegal (2017) [9].
Areas where onchocerciasis–loiasis are coendemic
present challenges for ivermectin treatment because of
the risk of SAEs in individuals with high Loa loa burden.
Environmental risk modelling helped to guide
distribution of ivermectin by mapping risk for L. loa
coendemicity in Cameroon (2007) [10].
Geostatistical mapping, based on RAPLOA data in 11
countries, informed where extra precautionary methods
or alternative strategies are needed to minimise SAE risk
(2011) [11].
Annual ivermectin distribution may not be sufficient to
achieve elimination in foci with high baseline
(precontrol) endemicity.
EPIONCHO and ONCHOSIM supported the shift to
6-monthly ivermectin treatment in highly endemic foci
in Africa (2014) [12, 13].
At the closure of the APOC in 2015, there was a need to
delineate current and alternative/complementary
intervention tools to reach elimination at the continental
level.
EPIONCHO and ONCHOSIM supported deliberations
and final APOC’s report on Strategic Options and
Alternative Treatment Strategies for Accelerating
Onchocerciasis Elimination in Africa (2015) [6].
Drug discovery and clinical trial design and analysis are
essential toward optimising alternative treatment
strategies based on the use of macrofilaricides (drugs that
kill adult O. volvulus).
Modelling facilitated analysis of clinical trials and
informed drug discovery and development by the
A�WOL Consortium (2015–2017) [14, 15].
Abbreviations: APOC, African Programme for Onchocerciasis Control; A�WOL, Anti-Wolbachia; OCP,
Onchocerciasis Control Programme in West Africa; RAPLOA, Rapid Assessment of Prevalence of Loiasis; SAE,
severe adverse event
https://doi.org/10.1371/journal.pntd.0008033.t001
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Results
Consortium principles
Five principles (Box 1) are the results produced by our distillation and synthesis of guidance
on good modelling practises we found in the literature. Adoption of these principles as consor-
tium principles is a result of about 2 years of engagement with the consortium membership.
See section Principles in practise for how adherence might be demonstrated.
Principle 1: Stakeholder engagement
Policy makers and other stakeholders should be involved early and throughout the process of
developing a model. Stakeholder engagement helps to ensure that the right balance is achieved
Fig 1. Study selection.
https://doi.org/10.1371/journal.pntd.0008033.g001
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between what decision makers and practitioners want and what modellers should and can pro-
vide to ensure that realistic policy options are being analysed and that proposed strategies for
disease control are culturally or socially acceptable. The process of distilling what modelling
needs to provide takes time to accomplish through dialogue. Stakeholders are essential to
ensure the best available knowledge and evidence are used in model design, calibration, and
validation. Finally, stakeholders are essential to interpret, translate, and integrate the implica-
tions of the findings.
Inclusion of stakeholders as authors in publications is important, including modeller stake-
holders. Lack of trust in modelling studies partly reflects limited representation of modelling
expertise from NTD-affected countries. The modelling community needs to support more
local development of capacity for modelling and make sure that local technical capacity is gen-
uinely engaged in discussions. Science on NTDs is increasingly changing in a positive way in
this respect, but modelling has a longer way to go on this.
Building confidence in a model’s usefulness is a gradual process [81]. For this reason, we
suggest that modelling studies choose to involve stakeholders early, ideally from the planning
phase [82]. We believe that models that are considered to be jointly owned by modellers and
Fig 2. Word cloud of the 1,054 modelling guidance statements. Relative word frequencies are represented by size of
the font.
https://doi.org/10.1371/journal.pntd.0008033.g002
Table 2. PRIME-NTD summary table.
Principle What has been done to
satisfy the principle?
Where in the manuscript is this described?
1. Stakeholder engagement
2. Complete model documentation
3. Complete description of data used
4. Communicating uncertainty
5. Testable model outcomes
https://doi.org/10.1371/journal.pntd.0008033.t002
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stakeholders have a higher chance of becoming impactful for policy. Of course, at times, some
stakeholders may not desire involvement of modelling teams, perhaps due to differences in
perspective or even conflicts of interest, but stakeholder involvement in model development
should remain a primary goal.
Principle 2: Complete model documentation
An analysis should be described in sufficient detail for others to be able to implement it and
reproduce the results [83]. Striving for this degree of clarity and transparency is good for repro-
ducibility [84, 85] and also motivates changes in conduct to raise quality [86, 87]. A protocol
often used to document agent-based models has shown success in raising their rigour [88].
Open-source software is only the first step of documentation. Deterministic and stochastic
models need to present the equations, diagrams, and event tables that describe their behaviour.
Agent-based models require more attention to completeness to be clear about what events can
happen to heterogeneous individuals and according to which probability distributions.
Information (data and code) generated in modelling should be maintained according to
common good software practises [89, 90] to ensure longevity [91], ideally on data-sharing plat-
forms [92]. The funding and resources for doing this maintenance could be considered when
planning the projects. In computational practises [90], ‘. . .decision makers who use results
from codes should begin requiring extensive, well documented verification and validation
activities from code developers’. Perfection is not the goal here, but thoughtful practises. Aca-
demic groups can transfer practical experience [89], so good computational practises also
belong in our discourse. We invite stakeholders to ask each other, and to ask modellers, which
quality controls are protecting the integrity of the modelling work.
Box 1: The five principles of the NTD modelling consortium
1. Don’t do it alone. Engage stakeholders throughout, from the formulation of ques-
tions to the discussions on the implications of the findings.
2. Reproducibility is key! Prepare and make available (preferably as open-source mate-
rial) a complete technical documentation of all model code, mathematical formu-
las, and assumptions and their justification, allowing others to reproduce the
model.
3. Data play a critical role in any scientific modelling exercise. All data used for
model quantification, calibration, goodness of fit, or validation should be
described in sufficient detail to allow the reader to assess the type and quality of
these analyses. When referencing data, apply Principle 2.
4. Communicating uncertainty is a hallmark of good modelling practise. Perform a
sensitivity analysis of all key parameters, and for each paper reporting model pre-
dictions, include an uncertainty assessment of those model outputs within the
paper.
5. Model outcomes should be articulated in the form of testable hypotheses. This
allows comparison with other models and future events as part of the ongoing cycle
of model improvement.
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Principle 3: Complete description of data used
It should be understandable how empirical data and evidence were used (or not used) for
model calibration, goodness-of-fit assessment, and partial validation (partial because models
are typically used to predict policy outcomes for which sufficient empirical data are not always
available). Employed data sets should be clearly described to allow readers to assess their qual-
ity and informativeness for specific model assumptions. The relevant context of data collection
should additionally be communicated along with model results. Descriptions of employed
data sets are central to building confidence in various assumptions in the model design. Model
assumptions may be justified by support from data, and when key assumptions do gain accep-
tance conditioned on data, they must be reconsidered with multiple data sets. If the assump-
tions are valid, they should continue to be supported by new data sets over time, which may
also lead to further dialogue on data requirements, before a model can be used to predict new
scenarios. New information may dictate alterations to a model.
Calibration and validation are crucial for determining how well the model has been speci-
fied and parameterised, guiding identification of key processes that should be included in
order to capture phenomena identified through model fitting to retrospective data and/or
through forecasting. Principle 3 helps us to assess parametric assumptions and model analyses,
as they may be limited by input data quality, and to identify data gaps and/or essential pro-
cesses that may lead to reformulation of structural assumptions.
Principle 4: Communicating uncertainty
Robust decisions are likely to be successful in the face of future uncertain events. Arguably one
of the most useful contributions of a model is to estimate how much uncertainty the future
may hold so that decisions may reasonably balance cost with risk. Therefore, stakeholders
might expect to receive a clear presentation of uncertainty relative to the decision problem.
Broad categories of uncertainty sources might be classed as fitted parameters, data inputs,
model structure, and stochasticity.
‘As with experimental results, the key to successfully reporting a mathematical model is to
provide an honest appraisal and representation of uncertainty in the model’s prediction,
parameters, and (where appropriate) in the structure of the model itself’ [93]. A sensitivity
analysis will demonstrate which parameters (or combinations of parameters) are most impor-
tant for the outcome of interest, thereby indicating for which parameters proper quantification
based on high quality data is most essential. By using realistic assessments of uncertainty in
parameter values and structural assumptions (i.e., parametric and structural uncertainty), it
should then be demonstrated in a so-called robustness or uncertainty analysis how the model
outcome is subject to overall uncertainty.
A consortium is a good forum (as exists for, among others, HIV, malaria, and NTDs) to
understand structural uncertainties between multiple modelling groups, including reducing
the overall level of uncertainty by ensembles [94] or other means of combining models. Open-
ness in assumptions can further help assessing the impact of poorly understood sources of
uncertainty on outcomes; for example, parameters called ‘fixed’ (i.e., an assumed value) may
need assessment, as well as assumptions about the fundamental processes underlying data pat-
terns. Modellers should excel in transparency of how uncertainty was estimated, and stake-
holders should not accept a projection without uncertainty bounds.
Principle 5: Testable model outcomes
Specific challenges to the use of forecasting arise in a policy context. Nevertheless, prediction
and falsification are of central importance in science [95, 96]. The life span of a model is
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typically long, and over time, the same model may be applied to different policy questions.
Model validation thus becomes an ongoing process. Models are often used to predict future
trends in infection and draw conclusions on specific policy questions in the absence of data.
However, data may become available at a later time and should then be used to further validate
the model, leading to a better model and more confidence in its predictions. Moreover, when
possible, forecasts may be made for a range of scenarios outside those for which data will be
collected, as data collection programmes may be expanded. Modelling studies aiming at defin-
ing a threshold or the most cost-effective strategy should also present expected future trends
for situations in which this threshold or strategy would actually be applied so that these trends
can potentially be compared with future data and proposed thresholds or strategies can be
reevaluated if necessary, or the context in which they apply can be better defined and
understood.
Model comparison, one of the main activities of the NTD Modelling Consortium [97],
requires multiple independent modelling groups working on each disease to explain collabora-
tively any differences between their model results on that disease. Agreement on a weighting
method allowing for an ensemble [98, 99], or otherwise placing results in a coherent frame-
work, supports clear interpretation of all results. Model comparisons are generally best done in
a masked manner, with data partitioned into a training set and a test set. A sufficient sample
size, together with probabilistic forecasting with proper scoring [100], can be used in forecast
comparisons, permitting objective and falsifiable comparisons. In looking to apply a model to
new or future problems, models cannot be truly ‘validated’ for a future scenario outside of
their training conditions, but an open and transparent collection of models, which have sur-
vived efforts at prospective testing, can provide more confidence in their prospective policy
analyses. Forecasting is garnering increasing interest outside NTDs, as shown by the Centers
for Disease Control and Prevention (CDC) sponsorship of an annual forecasting contest for
the United States influenza-like illness data [101, 102]. Guidelines for structured model com-
parisons were recently proposed to improve the quality of information available for policy
decisions [103]. Stakeholders can help build trust for objective comparison exercises by pro-
moting right incentives for inclusive comparisons.
Finally, we conjecture two additional benefits of objective testing that might be communi-
cated: (1) helping to avoid the danger of excessive agreement and ‘groupthink’—a failure to
challenge conventional wisdom with a truly searching inquisition, and (2) helping avoid to
bias.
Principles in practise: Policy-relevant items for reporting models in
epidemiology of neglected tropical diseases summary table
How can these five principles be upheld in practise? The principles are alive and well when we
regularly engage each other on demonstrations of the principles, express them in our publica-
tions, and demonstrate them in relationships with our stakeholders. Principles identify broad
themes that modellers should consider when reporting and communicating their research
findings. The reason we do this is to properly support the success of our stakeholders in mak-
ing use of modelling evidence.
We offer a summary table as a simple tool to write how each principle was fulfilled, or per-
haps what challenges were found. We call it the Policy-Relevant Items for Reporting Models in
Epidemiology of Neglected Tropical Diseases (PRIME-NTD) Summary Table (Table 2 and S1
Appendix). It is a means to promote engagement with the principles and to improve accessibil-
ity, communication, and reporting of modelling results. We promise to show our stakeholders
how we demonstrated the principles for them in a summary table to be included with
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presentations and publications on policy questions. We recommend more broadly that model-
lers follow a similar approach when making results available for policy matters. Stakeholders
are then invited to verify that the principles are in fact used in the modelling studies.
Discussion
Although many guidelines on modelling are already available [22, 23, 64], they are often not
implemented in practise. As part of an overall commitment to evidence-based decision-mak-
ing, we have reaffirmed existing recommendations regarding reproducibility, fidelity to data,
and accurate communication of uncertainty. We also found it important to extend existing
recommendations to emphasise the importance of stakeholder involvement (Principle 1) and
predictive testing [43, 104] (Principle 5). Stakeholder involvement can bring epidemiological
expertise, analytic relevance, and ultimately richer data. Striving for predictive testing by pro-
viding forward projections can provide a sharper model test than one that fits to existing data
alone, and it reflects a commitment to hypothesis testing and the scientific method. What
makes our contribution notable is that we are adopting the guidance ourselves and making a
commitment to our stakeholders that we are accountable to demonstrate our principles
throughout engagement.
Dialogue with stakeholders can help to improve the quality and responsiveness of quantita-
tive efforts to assess and inform health policy [105]. From formulating questions toward results
and potentially to implementation, the timing and nature of feedback should follow some
arranged plan for engagement that is not left to chance or whim. Fig 3 shows an example of a
collaborative process.
From the review, we also arrived at two philosophies that reflect some of our ideals. The
first is that modelling is an ongoing process, i.e., models should never be regarded as complete
or immutable. They should be repeatedly updated, and sometimes abandoned and replaced, as
new evidence or analyses become available to inform their structure or input. The second phi-
losophy is that the NTD Modelling Consortium strives for a mechanistic formulation of
Fig 3. Illustration of a collaborative process between modellers and stakeholders/decision makers. Each group brings something to the table at different
time points. The best modelling result with eventual impact is usually only obtained in collaboration. Although the process is depicted as linear, in practise
each node may connect back to stakeholders and modellers for continuous dialogue and discussion; policy implementation can also be reevaluated in light
of evidence.
https://doi.org/10.1371/journal.pntd.0008033.g003
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models whenever possible. This means incorporating into the models processes underlying
transmission and realistic operational contexts to measure things the same way a control or
research programme measures them. Moreover, the needs of public health and policy, we
believe, favour a mechanistic approach that permits testing counterfactual scenarios and helps
in communication with lay, nonmathematical stakeholders.
Depending on the perspective, it may be a limitation of our study that key stakeholders out-
side our consortium are not included as coauthors of our piece. By design, this work represents
our consortium’s understanding of what stakeholders have been asking us to do over the
course of ongoing engagements. Also a limitation of our review and qualitative synthesis is
that modelling fields outside of health were not searched, though they often relate well to the
modelling of diseases. The review was designed to thoroughly cover concepts appearing in
modelling guidance. It is not comprehensive of guidance issued. We abstracted some potential
indicators of future practise, such as having a statement of adherence (S1 Appendix—Table 2),
but we did not attempt to assess the use of guidance following their publication.
Guidelines for evidence synthesis allow unbiased integration of evidence in high-stakes
controversial settings [106]. Our study enhances communication required for properly evalu-
ating models, which complements recent initiatives by WHO on decision-making frameworks
inclusive of mathematical models [23, 107], qualitative systematic reviews [108], and opera-
tional research [109]. These frameworks extend the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) [110]. Expert groups such as WHO Initiative
for Vaccine Research sometimes evaluate models to support evidence synthesis, but there is
yet no standard way to integrate modelling into WHO guidelines development as there is for
clinical evidence [111]. One motivation for extending existing guidelines is that understanding
risk of bias in models [23, 31, 112] cannot be done well using the same approaches to bias risk
assessment for empirical studies.
The need for guidelines has been well established [113], which has led to accepted and prac-
tised standards for health research [114]. In this review, we found that only four [30, 38, 41,
45] of 57 guideline proposals had recognisable statements of commitment to their recommen-
dations such that the authors or others were actively encouraged to follow them. There may be
more adherents, but initial commitment is a striking indicator consistent with utilisation of
modelling guidance [37]. Additional successfully established modelling guidelines exist, for
example, on describing agent-based models [115] in theoretical ecology. In this example, the
authors later conducted a review of studies applying their guidelines [88], updating them
based on ongoing discussions with those who had adopted them to improve clarity and avoid
redundancy. A subtle outcome of our own work was that the process of synthesis was impor-
tant for the authors. Ongoing discussion throughout the synthesis process was shaped by our
intent to adopt the principles, which allowed a better understanding of how these might be
practised and of any potential barriers that might be encountered in doing so.
In conclusion, we believe that by distilling the five principles of the NTD Modelling Con-
sortium for policy-relevant work, and communicating our adherence to them, we will improve
as modellers over time and enjoy more effective partnerships in the meantime. We ask our
stakeholders to hold us to our promise. We also believe that the impact of applied modelling in
other fields may benefit from doing the same.
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